Key facts
- It has raised $290K; the latest was Seed Round ($240K) in May 2025.
- Notable investors include Venture Kick, ETH Zurich, Gebert Rüf Foundation, Madrid Food Innovation Hub.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for SURI BioTech
- ·The full record, as it builds
Funding rounds
No funding rounds for SURI BioTech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SURI BioTech
Developer of science-based health-promoting bacterial strains designed for use as probiotics with targeted mechanisms of action, operating in the life sciences and nutrition industry. The company offers probiotic strains developed through biological research and mechanistic validation for incorporation into health and wellness applications, enabling product developers and healthcare-focused organizations to address specific health functions with evidence-based microbial solutions.
- Sector
- Healthcare
- HQ
- Schlieren, Switzerland
- Founded
- 2020
- Website
- suribiotech.com/
- Ownership
- Privately Held (backing)
SURI BioTech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SURI BioTech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SURI BioTech in its N-PORT filings yet. We sweep new filings monthly.